Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Anesthesiology & Pain Medicine Genetics & Precision Medicine Pulmonology & Critical Care Physical Medicine & Rehab Nephrology Urology Emergency Medicine Ophthalmology Dermatology Hematology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Rheumatic Diseases

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Rheumatic Diseases

14 trials tracked for Rheumatic Diseases: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 63 citations.

14Trials tracked

2Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 3 2 Phase 2 2 Other / NA 10

Phase 3 A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients Completed · 63 cited
Phase 3 A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia Completed
Phase 2 A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Completed
Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee Completed
N/A Marathon and Enduron Polyethylene at Long-Term Follow-up Completed
N/A Performance-Enhancing Effects of Platelet-Rich Plasma (PRP) Injections Completed

Show 8 more trials

N/A Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial Completed
N/A Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications Completed
N/A Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia Completed
N/A PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders Completed
N/A Study Comparing Marathon Polyethylene and Enduron Polyethylene Acetabular Liners Used in Total Hip Arthroplasty Completed
N/A Patient-Reported Outcomes Measurement Information System Integration Into Rheumatology Clinical Practice Completed
N/A MyVoice:Rheum Decision Aid for Women With Rheumatic Diseases Completed
N/A Feasibility of a Mobile Application to Support Reflection and Dialog About Strengths in People With Chronic Illness Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Rheumatic Diseases: what the trials found

In a large-scale study, Rivaroxaban (10 mg) was evaluated for safety and efficacy in patients with rheumatic conditions. The time to the first occurrence of a composite of all symptomatic venous thromboembolism (VTE) and VTE-related death was 0.84 vs. 1.11 (p=0.136), while major bleeding rates were 0.28 vs. 0.15 (p=0.124). The rate of VTE-related death was 0.72 vs. 0.77 (p=0.751) ¹.

Treatment with TNX-102 SL Tablet (2.8mg) resulted in significant improvements in fibromyalgia symptoms and function at week 12. Specifically, the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score changed from baseline by -8.2 vs. -14.1 ², and the FIQR Function Domain Score changed by -4.4 vs. -10.3 ².

Recent results — preliminary, needs further review

LEVI-04 is currently being investigated in a Phase 2 trial ³.

For the clinician treating this condition

Rivaroxan (10 mg) demonstrated comparable safety and efficacy profiles regarding VTE and major bleeding events in large cohorts ¹.
TNX-102 SL Tablet (2.8mg) showed measurable improvements in both symptom scores and functional domain scores for patients with fibromyalgia ².

AI synthesis of 3 cited trials, updated Jul 16, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.